Lorlatinib plus Sacituzumab Tirumotecan with Peripheral ctDNA Guidance as First‑Line Therapy for ALK Fusion‑Positive NSCLC (ChiCTR) - Sep 16, 2026 - P2 | N=153 | Not yet recruiting | Sponsor: Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
Circulating tumor DNA • New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|